What drove the after-hours move in PRFN.SW stock on 06 Jan 2026?

The after-hours drop of **8.12%** was driven by large sell volume of **2,937,350** shares versus average **859,130**, low market depth, and no listed earnings update. Thin liquidity amplified price moves for PRFN.SW stock.

How does Meyka AI evaluate PRFN.SW stock?

Meyka AI rates PRFN.SW with a score of **67.07** (Grade B, HOLD). The grade weighs benchmark and sector comparisons, financial metrics, and forecasts. This is informational and not financial advice for PRFN.SW stock.

What are realistic price targets for PRFN.SW stock?

Meyka AI's model projects a base target of **CHF 0.050** (+38.18%), a bear at **CHF 0.020** (-44.75%), and a bull at **CHF 0.100** (+176.24%). Forecasts are model projections and not guarantees for PRFN.SW stock.

Is PRFN.SW stock suitable for long-term investors?

PRFN.SW stock is a speculative small-cap with negative EPS, thin liquidity, and clinical-stage risk. Long-term investors should review cash runway, trial milestones, and expect potential dilution before adding PRFN.SW stock to a core portfolio.

CH Stocks

PRFN.SW down 8.12% on 06 Jan 2026 after hours: volume 2.94M signals trader caution

ByDanny Kontos January 6, 2026January 6, 2026

PRFN.SW stock closed the session at CHF 0.036 on 06 Jan 2026 after hours, down 8.12% from the previous close. Trading volume surged to 2,937,350 shares, more than three times the average, making PRFN.SW one of the most active names on the SIX in after-hours trade. The move follows thin market depth and continued uncertainty around clinical progress and funding for Kinarus Therapeutics Holding AG. Traders should note the weak short-term moving averages and the discrepancy between the market price and the 50/200-day averages.